Recordati
New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease
Drug provided 'rapid and sustained' normalisation of mean urinary-free cortisol levels
FDA approves Recordati’s Cushing disease drug Isturisa
Important new treatment option for patients with rare disorder
Recordati acquires AstraZeneca blood pressure brands
Italian pharma firm obtains Seloken and Logimax
Recordati snaps up Swiss pharma company Pro Farma
Follows group's recent acquisition of Italian firm Italchimici
Recordati completes acquisition of Laboratorios Casen Fleet
Concludes €93m deal for Spanish gastroenterology specialist
Recordati promotes Andrea Recordati to COO
Move is part of a management reshuffle for the Italian pharma company
Year-end FDA approvals for Novartis, GSK drugs
Agency gives go-ahead to Cushing’s disease treatment Signifor and raxibacumab for inhalational anthrax
Novartis’ heart failure drug serelaxin meets targets
And FDA committee backs Signifor for Cushing's disease
Interview: Giovanni Recordati
The chairman and CEO of Recordati tells Linda Banks his plans for company expansion